BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30

• 

  Policy

  Sexual Harassment Scandals Hit Novartis and Pfizer’s Korea Units

  On Wednesday, KBR reported that a male employee at Novartis Korea reported to the company that his female boss sexually harassed him in September.

  November 30, 2017

   · 

  2 min read

   · 

  Alex Keown
• 

  Business

  Mettler-Toledo to Begin Layoffs in March, 69 Employees Affected

  Mettler-Toledo will begin to issue pink slips in March to employees at an upstate New York manufacturing facility.

  November 30, 2017

   · 

  2 min read

   · 

  Alex Keown
• 

  Deals

  Genmab and Johnson & Johnson Rake in the Bucks Together, Sparking Takeover Speculation

  Genmab just received a $20M milestone payment from Janssen Biotech.

  November 30, 2017

   · 

  2 min read

   · 

  Mark Terry
• 

  Biotech Bay

  3 Big Pharmas That Could be Winners for Investors in the Long Run

  Big pharma stocks have been longtime favorites among investors for several reasons.

  November 30, 2017

   · 

  1 min read
• 

  Biotech Bay

  3 Bioeconomy Stocks Investors Should Not Hesitate to Buy

  While the words biotech and biopharma are often used interchangeably, they aren’t the same thing - not even close, in fact.

  November 30, 2017

   · 

  1 min read
• Gilead Launches Hepatitis C Treatment in China at 20% of U.S. Price

  Gilead priced its Sovaldi treatment for hepatitis C at $8,938 in China - about one-fifth the current price in the U.S.

  November 30, 2017

   · 

  1 min read
• NeoPhore Scientific Founders Publish Breakthrough Immuno-Oncology Discoveries in Nature

  Clinical and now lab data suggest that many cancers with defective DNA repair appear to be highly sensitive to immune surveillance, including when the immune system is modified with agents that disrupt immune “checkpoints”.

  November 30, 2017

   · 

  2 min read
• 

  Drug Development

  Higher Death Rate Forces Bayer to Stop Xofigo/Zytiga Combo Late-Stage Study Early

  An IDMC told Bayer that it should unblind its Phase III clinical trial in prostate cancer in order to further analyze an increased number of fractures and deaths.

  November 30, 2017

   · 

  2 min read

   · 

  Mark Terry
• 

  Deals

  Astellas Takes Out Massachusetts’ Biotech Mitobridge in $390M Deal

  Astellas is pulling the trigger on an acquisition option from a partnership deal the two companies formed in 2013.

  November 30, 2017

   · 

  2 min read

   · 

  Mark Terry
• 

  Drug Development

  Bristol-Myers’ Lung Cancer Opdivo Trial Stopped Early for Superior Overall Survival

  Bristol-Myers Squibb has its eyes set on carving out a strong position in the lucrative Chinese lung cancer market.

  November 30, 2017

   · 

  2 min read

   · 

  Alex Keown